MediPal Holdings Corporation (TSE:7459) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

MediPal Holdings Corporation (TSE:7459) shareholders are probably feeling a little disappointed, since its shares fell 8.0% to JP¥2,287 in the week after its latest full-year results. It looks like the results were a bit of a negative overall. While revenues of JP¥3.7t were in line with analyst predictions, statutory earnings were less than expected, missing estimates by 2.1% to hit JP¥193 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

We check all companies for important risks. See what we found for MediPal Holdings in our free report.

Taking into account the latest results, the consensus forecast from MediPal Holdings' five analysts is for revenues of JP¥3.77t in 2026. This reflects a reasonable 2.6% improvement in revenue compared to the last 12 months. Statutory earnings per share are forecast to dip 7.7% to JP¥179 in the same period. In the lead-up to this report, the analysts had been modelling revenues of JP¥3.76t and earnings per share (EPS) of JP¥169 in 2026. So the consensus seems to have become somewhat more optimistic on MediPal Holdings' earnings potential following these results.

Check out our latest analysis for MediPal Holdings

The consensus price target was unchanged at JP¥2,436, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic MediPal Holdings analyst has a price target of JP¥2,510 per share, while the most pessimistic values it at JP¥2,320. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We can infer from the latest estimates that forecasts expect a continuation of MediPal Holdings'historical trends, as the 2.6% annualised revenue growth to the end of 2026 is roughly in line with the 2.9% annual growth over the past five years. Compare this with the broader industry (in aggregate), which analyst estimates suggest will see revenues grow 4.4% annually. So although MediPal Holdings is expected to maintain its revenue growth rate, it's forecast to grow slower than the wider industry.

The Bottom Line

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around MediPal Holdings' earnings potential next year. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that MediPal Holdings' revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for MediPal Holdings going out to 2028, and you can see them free on our platform here.

We also provide an overview of the MediPal Holdings Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.